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The hormone islet amyloid polypeptide (IAPP, or amylin) plays a role in glucose homeostasis but aggregates to form islet amyloid
in type-2 diabetes. Islet amyloid formation contributes to 𝛽-cell dysfunction and death in the disease and to the failure of islet
transplants. Recent work suggests a role for IAPP aggregation in cardiovascular complications of type-2 diabetes and hints at
a possible role in type-1 diabetes. The mechanisms of IAPP amyloid formation in vivo or in vitro are not understood and the
mechanisms of IAPP induced 𝛽-cell death are not fully defined. Activation of the inflammasome, defects in autophagy, ER stress,
generation of reactive oxygen species, membrane disruption, and receptor mediated mechanisms have all been proposed to play
a role. Open questions in the field include the relative importance of the various mechanisms of 𝛽-cell death, the relevance of
reductionist biophysical studies to the situation in vivo, the molecular mechanism of amyloid formation in vitro and in vivo,
the factors which trigger amyloid formation in type-2 diabetes, the potential role of IAPP in type-1 diabetes, the development
of clinically relevant inhibitors of islet amyloidosis toxicity, and the design of soluble, bioactive variants of IAPP for use as adjuncts
to insulin therapy.
1. Introduction
Hyaline lesions in the pancreaswere first describedmore than
110 years ago by Opie [1] and were later identified as amyloid.
The deposits were originally assumed to be composed of
insulin, fragments of insulin, or proinsulin, but 85 years after
Opie’s initial observation two groups independently identi-
fied the major protein component of islet amyloid as a 37-
residue polypeptide neuropancreatic hormone, now known
as islet amyloid polypeptide (IAPP) or amylin [2, 3] (Figure 1).
IAPP was subsequently shown to play an adaptive role in
metabolism and glucose homeostasis, helping to control
gastric emptying, glucose homeostasis, and suppression of
glucagon release and helping to regulate satiety [4–6].
IAPP has been found in all mammals studied to date
and the sequence is strongly conserved although there are
interspecies variations and these correlate with the ability to
form amyloid in vivo (Figure 1). The hormone is synthesized
as an 89-residue preprohormone and, after cleavage of the
signal sequence, the 67-residue proform is processed in the
Golgi and in the insulin 𝛽-cell secretory granule to yield the
mature hormone (Figure 2) [7, 8]. IAPP is stored with insulin
in the granule and is released in response to the stimuli that
lead to insulin secretion [9–11].
In this review we discuss the physical chemical properties
of IAPP, its normal function, the structure of the monomer,
and the amyloid fibril and then focus on amyloid formation
and the pathophysiology of IAPP. We also touch upon efforts
to design analogs of human IAPP (hIAPP) suitable for use
as adjuncts in insulin therapy. It is not possible to cover all
topics and all of the recent developments in IAPP research in
a limited review and the reader is referred to other articles
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Figure 1: Primary sequences of human CGRP and of IAPP from different species. Residues that differ from the human IAPP sequence are
in italics and underlined. The biologically active sequences all contain a disulfide bridge between Cys-2 and Cys-7 and have an amidated C-
terminus. Primates and cats have been reported to form islet amyloid while, rodents, and dogs do not. Ferret and porcine IAPP are reported to
be significantly less amyloidogenic than human IAPP.The ability of cow, bear, and puffer fish IAPP to form amyloid have not been investigated.
Islet amyloid is found in the degu, a rodent, but it is derived from insulin, not from IAPP. Only partial sequences are available for rabbit and
hare.
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Figure 2: Processing of human PreProIAPP to produce mature IAPP. (a) The primary sequence of the 89-residue human PreProIAPP. The
22-residue signal sequence is shown in italics; the N- and C-terminal proIAPP flanking regions are underlined. (b) Primary sequence of the
67-residue proform of human IAPP. Pro-hIAPP is cleaved by the prohormone convertases PC(1/3) and PC2 at two conserved dibasic sites,
indicated by arrows. The amidated C-terminus is produced after further processing by CPE/PAM. (c) The sequence of the mature 37-residue
human IAPP. The biologically active peptide has an amidated C-terminus and a disulfide bridge between Cys-2 and Cys-7.
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in this issue for coverage of other topics and for alternative
views. We do not discuss efforts at inhibitor design as they
are described in other articles in this issue and have been
reviewed elsewhere [12]. A number of review articles have
been published in recent years which provide additional
information on various aspects of the biology and biophysics
of IAPP [4–6, 12–15].
Much has been learned about the role of IAPP in glucose
metabolism, and the role of islet amyloidosis in metabolic
disease, but there is still much that is unclear. The site of
initiation of amyloid formation in vivo is controversial. The
mechanism(s) of IAPP amyloid formation in vivo and in vitro
are still not understood nor are the factors which trigger
islet amyloidosis in type-2 diabetes (T2D). The nature of
the toxic species generated during IAPP amyloid formation
is not well defined and the mechanisms of 𝛽-cell death
are not completely understood. The possible role of IAPP
aggregation in the complications of diabetes has yet to be
fully defined and the potential role of IAPP in type-1 diabetes
remains to be elucidated [16–18]. Unfortunately, inhibitors of
IAPP 𝛽-cell toxicity are less well developed than for other
amyloidogenic proteins and no clinically relevant inhibitors
of islet amyloidosis toxicity have yet been described. There
is also interest in developing bioactive, nontoxic analogs of
IAPP with improved solubility for use as adjuncts to insulin
therapy and for potential coformulation with leptin.
2. The Physical Chemical Properties of IAPP
and the Importance of the 20–29 Region in
Amyloid Formation
hIAPP is a relatively hydrophobic polypeptide but con-
tains several positively charged residues, Lys-1, Arg-11, and,
depending upon the pH,His-18 (Figure 1).There are no acidic
residues in the molecule and the C-terminus is amidated;
thus its pI is above the pKa of the Tyr and Lys residues. The
polypeptide is positively charged at and below physiological
pH with a net charge ranging from 2 to 4 depending
upon the pKa’s of the N-terminus and His-18 and the pH.
The net positive charge on the molecule is important for
interactionswith negatively charged, nonphysiologicalmodel
membranes and for interactions with sulfated proteoglycans
of the extracellular matrix. The sequence of hIAPP contains
an unusually large number of Asn and Ser/Thr residues for its
size, 6 and 10, respectively. There are three aromatic residues
including a conserved C-terminal Tyr, a conserved Phe at
postion-15, and a second Phe at postion-23.
IAPP belongs to the calcitonin related peptide fam-
ily which is comprised of adrenomedullin, 𝛼- and 𝛽-
calcitonin gene-related peptide (CGRP), intermedin, and
calcitonin. The peptides all share key posttranslational mod-
ifications; they all have an amidated C-terminus and contain
an intramolecular disulfide bridge near the N-terminus
(Figure 1). IAPP is most similar to CGRP. The two peptides
have reasonable sequence similarity but diverge the most
within the segment corresponding to residues 20 and 29
[19]. hIAPP is aggressively amyloidogenic in vitro, but CGRP
does not form amyloid. These observations led to the initial
hypothesis that the sequence of the 20 to 29 region dictates
the ability of IAPP to form amyloid and were supported
by studies with ten residue peptides derived from residues
20 to 29 of hIAPP [19, 20]. Not all mammals form islet
amyloid; notably mice and rats do not [19, 21]. Comparison
of the rat/mouse sequence to the sequence of hIAPP, together
with early in vitro experiments, appeared to confirm the
hypothesis that the ability to form amyloid is controlled by
the identity of the 20–29 segment [20, 21]. hIAPP and rat
IAPP (rIAPP) differ at six positions and five of these are
between residues 23–29. Of particular note, the rat sequence
contains three Pro residues at positions 25, 28, and 29,
while the human sequence has none (Figure 1). Pro is highly
energetically unfavorable in a 𝛽-sheet and is a well-known
disrupter of secondary structure. Consequently, the inability
of rat IAPP to form amyloid has been attributed to the Pro
substitutions [21]. These important early studies led to the
view that the ability of IAPP to form amyloid in vitro and
in vivo is determined by the primary sequence in the 20–29
region; however the situation is more complex.
Other fragments, in addition to the 20–29 segment of
hIAPP, were subsequently shown to be capable of forming
amyloid in isolation, arguing that the 20–29 region is not
the only amyloidogenic segment of the polypeptide. These
include peptides comprised of residues 30–37, 8–20, and 10–
19 and even smaller fragments from the 10–19 region [22–
25].The work with the smaller fragment led to the suggestion
that this region of the chain is likely important for formation
of initial hIAPP hIAPP contacts during aggregation [25].
Peptide array studies, in which a family of overlapping
peptides that span the entire region of hIAPP were tested
for hIAPP binding, confirmed the importance of this region.
Subsequent X-ray crystallographic structural studies with a
truncated hIAPP maltose binding protein fusion construct
revealed pairs of hIAPP molecules making interprotein con-
tacts in this region [26]. Interestingly, the region of hIAPP
that appears to be important for self-contacts also appears to
be important for interactions with insulin and with the A𝛽
peptide of Alzheimer’s disease [27, 28].
Studies on intact hIAPP also indicate that the 20–29
segment is not the sole amyloidogenic determinant. Multiple
Pro substitutions outside of the 20–29 region abolish amyloid
formation by hIAPP and replacement of Asn-14 or Asn-21
has been reported to do so as well [29, 30]. Conversely,
substitution of residues 18, 23, and 26 in rIAPP by the
corresponding amino acids of hIAPP led to a weakly amy-
loidogenic polypeptide even though it still contained the 3
Pro residues of rIAPP [31]. Thus, the 20–29 sequence cannot
be the only factor governing amyloid formation, but there is
no doubt that it is important and single proline substitutions
within the 20–29 segment have been shown to significantly
reduce the amyloidogenicity of hIAPP as have double N-
methyl modifications in this region [32–34].
3. The Structure of the IAPP Amyloid Fibril
High resolution models of the IAPP amyloid fibril have
been developed based upon solid state NMR studies, and on
X-ray diffraction studies of microcrystals of small peptide
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fragments of hIAPP which form steric zippers. Although
they differ in their details, mainly in the location of the C-
terminal 𝛽-strand, they are broadly similar; each is made up
of two symmetrically related columns of IAPP monomers
(Figure 2) [35, 36]. Monomers within each column pack on
top of each other to generate a U-shaped structure with the
𝛽-sheet hydrogen bonds between adjacent IAPPmolecules in
one column. Each column contains two in-register parallel𝛽-
sheets. In the solid state NMR model, the N-terminal strand
encompasses residues 8 to 17 and the C-terminal strand
residues 28 to 37. The fragment based model differs from
the NMR model in the location of the C-terminal 𝛽-sheet;
it places residues 23 to 37 in the C-terminal 𝛽-sheet and
residues 8 to 17 in the N-terminal 𝛽-sheet. Two structures
were proposed based on the solid state NMR data, both of
which are consistent with the experimental restraints. The
major differences between the two are the register of the
side chains. In one structure, Arg-11, Ala-13, and Phe-15 are
all solvent-exposed, and in the other they project into the
core of the fibril. Burial of a charged Arg side chain will
be energetically unfavorable and the structure in which it is
exposed seems more likely.
Independent amide H/D exchange measurements and
two-dimensional infrared (2DIR) studies are largely consis-
tent with the NMR model. Amide H/D exchange rates are
sensitive to H-bonding and have recently been used to study
amide proton solvent protection in hIAPP amyloid fibrils.
The data are consistent with anN-terminal 𝛽-strandmade up
of residues 8 through 18 and a C-terminal strand comprised
of residues 26 to 37 [37]. 2DIR line widths are sensitive
to local dynamics and can be combined with molecular
dynamics simulations to probe protein structure. A combined
experimental 2DIR and computational study of hIAPP fibrils
has been reported and the pattern of experimental line widths
is consistent with predictions based upon the solid stateNMR
model [38].
Does the fact that the solid stateNMRand fragment based
models differ from one another mean that one is correct
and one must be wrong? Not necessarily. It is important to
emphasize that both structures are models based on, and
consistent with, separate sets of experimental data which
are sufficient to constrain the models but not to completely
define a precise, three-dimensional, high resolution structure.
Given the very different data used to construct the models,
it is striking and reassuring that they share many common
features. In addition, it is important to bear in mind that
amyloid fibrils are polymorphic and thus the alternative
structures couldwell represent different polymorphs [39–42].
An interesting alternative model, which differs from both
the NMR and the fragment based model, has been proposed
based upon EPR studies conducted with a set spin labeled
variants of hIAPP incorporated into the polypeptide via
Cys mutations. The method is more perturbing than the
NMRor crystallographic approach since the spin labels could
represent a large perturbation at a particular site, given
the necessity of introducing a Cys and given the size of
the spin label and its linker. However, the study involved
an impressive number of variants and included analysis of
electron microscopy data as well [43]. The model shares
several of the general features of the NMR and fragment
based models in that each IAPP molecule bends into an
approximate U-shaped structure and contains two 𝛽-strands;
in the case of the EPR model, these are made up of residues
12 to 19 and of 31 to 36 with residues 7 to 10 in a transition
region.The location of ordered secondary structure is broadly
consistent with that proposed from the NMR studies. The
key difference between the EPR based model and the others
is that the two strands in an IAPP monomer are staggered
by about 15 A˚ with respect to each other in the EPR model;
the staggered relationship leads to a left-handed twist. The
authors proposed that the EPR structure could represent an
alternative polymorph.
Strikingly, most of the 20–29 segment is not part of
the ordered 𝛽-sheet structure in the NMR and EPR based
models but rather forms a loop which links the two 𝛽-strands
(Figure 3). A loop should be able to accommodate mutations,
making it unclear why mutations in this region have such
a dramatic impact on amyloid formation. Time resolved
2DIR studies provide a possible resolution of the apparent
conundrum [44]. Under the conditions of the 2DIR studies, a
transient “nonnative” intermediate is formed that has parallel
𝛽-sheet structure localized in residues 23–27. This structure
must ultimately be disrupted to form the loop which is found
in the fibril. The location of the transient 𝛽-sheet offers an
explanation for the sensitivity of IAPP amyloid formation
to some of the substitutions within the 20–29 region [44].
Along these lines, stabilization of turn structures in the A𝛽
peptide of Alzheimer’s disease can enhance significantly the
rate of amyloid formation [45]. The structure derived from
the fragment model can rationalize the sensitivity of amyloid
formation to substitutions within the region of residues 24
to 29. This segment is well ordered in the model and both
Ser-28 and Ser-29 are involved in critical contacts (Figure 3),
rationalizing why the three Pro residues in rat IAPP impact
amyloid formation.
4. Spontaneous Deamidation of
Asn Residues Can Impact the Ability of
hIAPP to Form Amyloid
The six Asn residues in hIAPP render the molecule suscep-
tible to deamidation. Spontaneous Asn deamidation is one
of the most common nonenzymatic posttranslation modifi-
cations of proteins and is believed to play a role in amyloid
formation by other polypeptides [46]. Deamidation of Asn
occurs via formation of a cyclic succinimide intermediate
which leads to the conversion of an Asn residue into L or D
Asp or L or D iso-Asp. The final product depends upon how
the ring is opened. In all cases a neutral residue is replaced
by a negatively charged residue which reduces the net charge
of hIAPP and could thus reduce its solubility. Generation
of iso-Asp introduces another rotatable bond in the peptide
backbone which will impact its conformational propensities,
while generation of a D amino acid alters significantly the
allowed regions of the 𝜙-𝜑 plot. Asn deamidation has been
shown to accelerate hIAPP amyloid formation in vitro and
to lead to changes in the morphology of hIAPP amyloid
Journal of Diabetes Research 5
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Figure 3: A model of the hIAPP fibril based on crystal structures of small peptide fragments of hIAPP. (a) Primary sequence of human IAPP.
Residues color-coded red are found in the first 𝛽-strand in the fibril; those colored blue in the second 𝛽-strand and the ones located in the
partially ordered loop that connects the two stands are colored green.The first seven residues are believed to be outside of the structured core
of the fibril and are color-coded black. (b) Top down view of the model with several key residues shown.The N-termini are labeled. (c) View
rotated by 90∘ showing the arrangement of the two stacks as a ribbon diagram.
fibrils [47]. Deamidation has also been shown to promote
amyloid formation by otherwise nonamyloidogenic peptide
fragments of hIAPP [48]. Of practical concern, deamidation
is sensitive to the choice of buffer and this should be kept in
mind when conducting experiments that involve incubating
the polypeptide for significant lengths of time.
It is not known if deamidation plays a role in islet amyloid
formation in vivo. A significant challenge with any potential
study will be to define a causal relationship. The observation
of deamidated material in isolated islet amyloid deposits
would not prove that deamidation leads to amyloid formation
since deamidation could have occurred after formation of
the amyloid fibril. An issue for any biophysical study is the
challenge of characterizing the highly heterogeneous ensem-
ble that can arise from six potential sites for deamidation
with five potential substitutions at each site (the normal Asn
residue plus the 4 possible deamidation products).
5. Mutational Analysis of Amyloid Formation
by IAPP
The only natural mutation found in the mature sequence
of hIAPP is a Ser to Gly missense mutation at position 20.
This mutation, which is found at low levels in certain Asian
populations, has been proposed to lead to a slightly higher
risk of diabetes, although the statistical significance has been
questioned [4, 49–52]. The mutation accelerates amyloid
formation in vitro, but the mechanism by which it does so
is unknown. Stabilization of globular proteins or acceleration
of their folding rate by substitution of an L-amino acid with
Gly is often due to the fact that Gly can relieve steric clashes
and/or adopt “left handed” conformations with a positive 𝜙-
backbone dihedral angle that are energetically unfavorable for
an L-amino acid. However, the side chain of Ser-20 makes
no obvious clashes in the existing models of IAPP amyloid
fibrils and it adopts a normal 𝜙-backbone dihedral angle. In
addition, Ser-20 is located in the loop/bend region between
the two 𝛽-strands in all of the models of hIAPP amyloid
fibrils. The reason for the significant enhancement in the rate
of amyloid formation by the Ser-20 to Gly mutation of hIAPP
is still unknown.
Quantitative mutational studies of amyloid fibril stability
and of the kinetics of amyloid formation are much more
challenging than studies with soluble, monomeric, globular
proteins. There are rigorous, well-established methods for
determining the stability of soluble proteins, but this is not
always the case for amyloids. Solubility measurements give
simple interpretable apparent free energies, if the process is
reversible, if the soluble phase is composed of monomers,
and if activity effects can be ignored, but it is difficult to
verify these assumptions. An added complication is that
mutations can lead to different polymorphs and might alter
the mechanism of self-assembly. Furthermore, studies that
report that a mutation abolishes amyloid formation may
have simply not examined the protein for a long enough
time. In spite of these caveats, mutational analysis of amyloid
formation has provided useful insight and systematic studies,
such as proline and alanine scans, have been reported for a
number of amyloidogenic proteins, but not for hIAPP.
No systematic analysis of all of the positions of IAPP has
been reported, although a number of mutational studies have
been conducted [12, 30, 51–55]. It can be difficult to compare
different studies since a range of conditions have been used
and the rate of IAPP amyloid formation is sensitive to small
changes in buffer composition, temperature, added salt, pH,
the degree of agitation, and even the volume of sample used
in experiments. Residual TFA from HPLC purification can
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affect amyloid formation and issues with lot to lot variability
of ostensibly pure commercial IAPP have been reported [56].
A further complication arises from the fact that many studies
have made use of a truncated fragment of IAPP which lacks
the first seven residues (IAPP
8–37). These residues are outside
of the ordered amyloid core in both the NMR and X-ray
models, but they might still affect the stability of the amyloid
fibers. If nothing else, the truncation removes the charge on
the side chain of Lys-1 and, depending upon whether or not
the N-terminus is acetylated, the charge on the N-terminus
as well. These considerations mean that considerable caution
needs to be employed when comparing data generated in
different laboratories. Unfortunately some papers do not
provide all of the details required to repeat measurements.
hIAPP contains three aromatic residues: Phe-15, Phe-23,
and Tyr-37. Phe-15 and Tyr-37 are strictly conserved amongst
known IAPP sequences while Phe-23 is often replaced with
Leu (Figure 1). Aromatic-aromatic, hydrophobic-aromatic,
and aromatic-cation interactions have been proposed to be
important in amyloid formation. Early studies, involving Ala
scanning of short peptides derived from IAPP, supported
this conjecture [57, 58]. Subsequent studies that employed
more conservative aromatic to Leu substitutions revealed that
aromatic residues were not required for amyloid formation
by the full length polypeptide, although mutation of the
aromatic residues impacts the rate of self-assembly [54, 55,
59, 60]. For example, replacement of all three of the aromatic
residues in hIAPP by Leu leads to 5- to 8-fold slower amyloid
formation [54].
A systematic examination of the role of different Asn
residues in hIAPP in amyloid formation and assembly has
also been reported [30]. The authors used the approxi-
mately isosteric substitutions of Leu for Asn and found
that substitution of different Asn residues had drastically
different consequences on amyloid kinetics.The truncated 8–
37 hIAPP fragment was used as background in this study.The
Asn14Leu and Asn21Leu mutants did not form amyloid on
the experimental timescale of these studies.
Asn to Leu mutants offer a nice example of the value of
using isosteric substitutions. The Leu side chain has approxi-
mately the same size and shape as Asn, but cannot hydrogen
bond and is nonpolar. This allows a simpler interpretation of
the data than would experiments involving less conservative
replacements. A similar approach could be used to probe
the role of the different Thr residues via Val substitutions.
Isosteric replacement of other residues in hIAPP requires
nongenetically coded amino acids. The polypeptide can be
prepared by solid phase peptide synthesis making such
studies possible. For example, substitution of Ser with 2-
aminobuytric acid represents an isosteric replacement and
would allow the role of the OH group to be probed. This
is of interest because Ser-28 and Ser-29 are located at the
interface of the two symmetrically related columns of hIAPP
monomers in the fibril structure and are involved in networks
of hydrogen bonded interactions (Figure 3). In addition, Ser-
19 and Ser-20 are highly conserved in known IAPP sequences
and Ser-34 are strictly conserved, making them interesting
targets for future analysis (Figure 1).
The literature on IAPP mutations has been critically
reviewed in 2013 and, in the interest of space, we refer the
interested reader to that work for a more detailed discussion
[12]. However, some additional mutants have been analyzed
since then and we briefly summarize the new results. The
role of the amidated C-terminus has been examined, as has
the role of His-18 [60]. NMR studies of a nonphysiological
variant of hIAPP with a free C-terminal carboxyl group
provided evidence for intermolecular interactions involving
His-18 and Tyr-37 at pH 5.5 and it was suggested that
these interactions play a role in the early stages of amyloid
formation by hIAPP. However, a subsequent study revealed
that mutants which were designed to disrupt the putative
His-Tyr interaction actually accelerated amyloid formation,
indicating that the interaction is not essential for amyloid
formation [60]. Replacement of His-18 with either a Gln or
Leu significantly accelerated amyloid formation. Analysis of
the His-18 Gln mutant revealed that the rate of IAPP amyloid
formation was still pH dependent between pH 5 and 8,
thereby showing that the charge state of the N-terminus is an
important factor modulating the rate of amyloid formation,
even though the N-terminal region of IAPP is not part of
the core 𝛽-sheet structure. Amdiation of the C-terminus
was shown to accelerate IAPP amyloid formation relative to
the variant with a free C-terminus, even though amidation
increased the net charge on the polypeptide.
6. IAPP Is Synthesized as a Preprohormone
IAPP is synthesized as a 89-residue preproform (Figure 3)
[7]. The first 22 amino acids constitute the signal sequence
and the next 67 amino acids are the proform (proIAPP).
The N- and C-terminal flanking regions of proIAPP are
cleaved by the prohormone convertases PC2 and PC1/3 [7].
ProIAPP is processed in theGolgi and in the insulin secretory
granule [7, 8]. Amidation of the C-terminus is a multistep
process. The first C-terminal cleavage leaves a Gly-Lys-Arg
tripeptide sequence as the new C-terminus. The dibasic Lys-
Arg pair at the C-terminus is removed by carboxypeptidase
and the Gly acts as the nitrogen donor for amidation of the
C-terminal Tyr by the peptidyl amidating monooxygenase
complex (PAM). Disulfide bond formation leads to mature
IAPP (Figure 3). Incorrect processing of proIAPP has been
proposed to play a role in islet amyloid formation in vivo,
but relatively little work has been done in vitro on amyloid
formation by partially processed IAPP [8, 61–65].
Mature IAPP is stored in the insulin secretory granule
and is found in the halo region of the granule, while insulin
is located in the dense core. The concentration of IAPP
in the granule is noticeably lower than that of insulin,
about 1%-2% of the insulin level, but it is still much higher
than that required to promote rapid amyloid formation in
vitro [66, 67]. Thus, there must be factors that prevent the
irreversible aggregation of IAPP in the granule. The low pH
environment of the granule contributes since the rate of IAPP
amyloid formation is slower at intragranule pH [60, 68–70].
Soluble insulin is one of the most potent inhibitors of IAPP
aggregation and may play a role in modulating intragranule
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aggregation; however insulin is in a semicrystalline state in
the granule [71–75].
7. IAPP Has Multiple Physiological Roles
In rats, the circulating concentration of IAPP is reported to
be on the order of 3 to 5 picomolar and to rise to 15 to 20
picomolar with elevation of blood glucose [4, 5]. However,
the local concentration after release from the granule will
be much higher and this is the more relevant number
for amyloid formation. The effects of IAPP are receptor
mediated, but are still not fully understood. IAPP receptors
are generated from coexpression of the calcitonin (CT)
receptor with receptor activity-modifying proteins (RAMPs)
[76–79]. Interaction with RAMPs changes the specificity of
the CT receptor towards IAPP.TheCT receptor has two splice
variants and there are 3 relevant RAMPs, so there are six
different subtypes of IAPP receptors. It is not known whether
different receptor subtypes are active in the peripheral tissue
and in the CNS. There are no approved small molecule
agonists of IAPP receptors.
hIAPP plays a role in maintaining glucose homeostasis,
in controlling gastric emptying, and in the suppression of
glucagon release [4–6]. The hormone is also involved in
controlling satiety and acts as an adiposity signal [80–82].
hIAPP’s anorectic effect appears to be mediated mainly at
the area postrema of the central nervous system [81]. IAPP
has been proposed to help regulate blood glucose levels by
inhibiting insulin secretion [83, 84]. Studies conducted with
concentrations of hIAPP that are higher than the physio-
logical level have led to suggestions that the polypeptide
may inhibit the synthesis of glycogen and insulin-stimulated
glucose uptake in isolated rat skeletal muscle [85]. Weight-
lowering effects induced by IAPP have been reported in
obese rats and humans. Animal studies with food-matched
controls have led to the hypothesis that weight loss occurs via
mechanisms that are similar to those found with enhanced
leptin sensitivity [82, 86, 87]. Several recent reviews provide
a more in-depth view of the physiological role of hIAPP
[4, 5, 88].
8. Monomeric IAPP Does Not Fold to
a Compact Structure in Solution, but It Is
Not a Random Coil and Can Form Helical
Structure on Model Membranes
Monomeric hIAPP does not fold to a compact globular
structure and can be classified as an intrinsically disordered
protein, but it is not a random coil. NMR chemical shift
studies have shown that the region encompassing residues 5–
20 of rIAPP and hIAPP transiently sample helical 𝜙,Ψ angles
in solution, but the level of persistent helical structure is low
[89, 90]. More persistent helical structure is formed when
hIAPP interacts with negatively charged model membranes
[90–94]. NMR based structures of IAPP fragments and of full
length IAPP in membrane mimetic environments have been
reported [92–94]. hIAPP adopts a helix-kink-helix structure
on model membranes with the helices located between
residues 5 to 17 and 20 to 27. Analysis of peptide fragments
has shown interesting differences in the structure of rIAPP
and hIAPP in the presence of micelles which are ascribed to
the His-18 to Arg substitution in rIAPP. The 1–19 fragments
of both peptides adopt similar 𝛼-helical structures in the
presence of detergent micelles, but they bind to micelle in
different orientations [93, 95]. hIAPP
1–19 inserts more deeply
into the nonpolar core of the membrane, while rat IAPP
1–19,
with its Arg substitution binds near the surface. hIAPP
1–19
binds near the surface, similar to rat IAPP
1–19, at acidic pH
when His-18 is protonated, indicating that the net charge of
residue 18 is important in controlling the orientation [93, 95].
Membrane-bound structures of full length human and rat
IAPP also reveal similarities in the N-terminal half of the
molecule, but there are differences in the C-terminal half.
The N-terminal portion of both polypeptides adopt 𝛼-helical
structure [92–95]. hIAPP has a partially helical C-terminal
region, but theC-terminal region of rat IAPP,with itsmultiple
Pro residues, is disordered [92]. The role of IAPP membrane
interactions in amyloid formation and in toxicity is discussed
in subsequent sections of this review and more detailed
information about membrane bound conformations of IAPP
can be found in other reviews in this issue.
9. The Parallel, In-Register, 𝛽-Sheet
Architecture of the hIAPP Fibril Has
Important Energetic Consequences
Amyloid fibrils form a so-called “cross-𝛽” architecture with
the interstrand hydrogen bonds oriented parallel to the long
axis of the fibril and the 𝛽-strands oriented perpendicular
to the long axis. The parallel, in-register, 𝛽-sheet structure
of amyloids generates effectively infinite arrays of stacked
identical residues and this has important energetic conse-
quences. The in-register arrangement implies that there can
be significant electrostatic interactions in amyloids. In hIAPP,
Arg-11 and His-18 are in the structured core of the fibril, or
immediately adjacent to it, arguing that they will make net
unfavorable electrostatic contributions to the stability of the
fibril. Calculations performed at the level of the linearized
Poisson-Boltzmann (PB) approach show that Arg-11 makes
significant unfavorable electrostatic interactions but that His-
18 does not do so when its side chain is neutral. In this
case, the desolvation penalty paid by His-18 is overcome by
specific interactions with the imidazole ring [96]. His-18 in
hIAPP is replaced by Arg in rIAPP and, based upon the PB
analysis, this substitution is expected to destabilize the cross-
𝛽 structure. Consistent with this hypothesis, experimental
studies argue that the His-18 to Arg substitution contributes
to the inability of rIAPP to form amyloid [31]. A number
of groups have independently examined the role of His-18
via pH dependent studies or by computational approaches,
and all have concluded that amyloid formation by hIAPP is
significantly slowed when the residue is protonated [60, 97–
99]. One complication with the simple interpretation of pH
dependent studies is that the rate of hIAPP amyloid formation
is also affected by the protonation state of the N-terminus
[60, 98].
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Linearized PB calculations may not be rigorously valid
for a strongly coupled system and thus the quantitative
details of the analysis should be interpreted with caution.The
problem of electrostatic interactions in amyloids has not been
studied in detail and seems ripe for further investigation.The
pattern of like charges in amyloid fibrils is reminiscent of
other systems with repetitive arrangements of charges such
as DNA and approaches that have been used to analyze
the energetics of DNA should be applicable to amyloids.
Unfavorable electrostatic interactions are also likely to arise
from the N-terminus of IAPP. Lys-1 is the region of highest
charge density in the polypeptide and is expected to make
unfavorable electrostatic interactions in the amyloid fibril,
even though that region is not part of the well-ordered 𝛽-
sheet core.
The importance of electrostatic interactions in hIAPP
amyloid is also reflected in the dependence of the kinetics
of hIAPP amyloid formation on ionic strength and on the
type of salt. In particular, the rate amyloid formation is
significantly accelerated with increasing salt and the effects
depend on the choice of anion. An excellent correlation with
the anion selectivity series was observed at low andmoderate
salt concentrations, strongly arguing that anion binding plays
a role in the effects [96]. A corollary of this study is that
the choice of buffer is expected to impact the rate of hIAPP
amyloid formation even when the pH and ionic strength
are kept constant. The net positive charge on hIAPP has
been exploited to develop charge based inhibitors of amyloid
formation and is important for interactions with HSPGs and
with anionic membranes (discussed in subsequent sections)
[100].
The parallel in-register structure also leads to networks
of interactions involving polar uncharged residues. In the
fragment model, Ser-28 and Ser-29 are involved in a steric
zipper and make extensive hydrogen bonding interactions
[26]. Ser-29 in particular forms an interesting network of
interpolypeptide hydrogen bonds involving other chains in
the same column of monomers as well as interactions with
Ser-29 in the symmetry related column (Figure 3). As previ-
ously noted, hIAPP contains a large number of Asn residues
and the kinetics of amyloid formation are sensitive to isosteric
Asn to Leu substitutions. Asn side chains contain both a
hydrogen bond donor and acceptor and are hence capable
of forming networks of interpolypeptide hydrogen bonds.
Asn ladders, hydrogen bonded networks of Asn residues,
have been postulated to play an important role in stabilizing
amyloid fibrils and MD simulations on a model 5-mer, Asp-
Phe-Asn-Lys-Phe, derived from human calcitonin support
a role for Asn-Asn stacking interactions in amyloid fibril
stability [101].
10. In Vivo Islet Amyloid Deposits Contain
Heparan Sulfate Proteoglycans and
Other Factors as well as Incompletely
Processed ProIAPP
Islet amyloid contains the heparan sulfate proteoglycan
(HSPG) perlecan, apolipoprotein E (apoE), and serum
amyloid P component (SAP) [102, 103] in addition to IAPP.
There is no correlation between the presence of SAP and
islet amyloid deposition. ApoE mouse knockouts do not
affect islet amyloid formation and there is no correlation
between levels of apoE and islet amyloid formation in hIAPP
transgenic mice [103]. This contrasts with the correlation
between apoE and amyloid formation in Alzheimer’s disease.
Secretion of an incompletely processed proIAPP intermediate
that includes the N-terminal prosequence, denoted here by
Npro-hIAPP, has been reported to be increased in T2D and
to be incorporated into islet amyloid [4, 62, 63].
11. Model Glycosaminoglycans and
Model Membranes Containing Anionic
Lipids Accelerate IAPP Amyloid
Formation In Vitro
hIAPP is cationic and ionic interactions facilitate its bind-
ing to negatively charged membranes, negatively charged
biopolymers, and negatively charged surfaces. It is not known
if perlecan is associated with islet amyloid because in vivo
amyloid fibers are long-lived structures that present HSPG
binding sites, or because HSPGs directly promote amyloid
formation, but it is well documented that the glycosaminogly-
can (GAG) chains of HSPGs catalyze hIAPP amyloid forma-
tion in vitro [64, 104]. There is indirect evidence that HSPGs
promote islet amyloid formation in vivo. Overexpression of
heparanase in a double transgenic mouse model that over-
expresses hIAPP reduced the amyloid load, while inhibition
of GAG synthesis reduced hIAPP amyloid deposition in
cultured islets [105, 106].
The factors that trigger islet amyloid formation in vivo
are still mysterious, but one model postulates binding of
the Npro-hIAPP processing intermediate to the GAG chains
of perlecan [61, 62, 64]. The N-terminal extension actually
makes hIAPP less amyloidogenic and more soluble but
enhances interactions with GAGs. In this model, incom-
pletely processed hIAPP binds to HSPGs, thereby leading to
a high local concentration of the peptide which promotes
aggregation and amyloid fibril formation. The resulting
aggregates then recruit more Npro-hIAPP and fully pro-
cessed IAPP. In support of themodel, interactionswithmodel
GAGs have been shown to accelerate NproIAPP amyloid
formation in vitro and the resulting fibrils can seed amyloid
formation by fully processed mature hIAPP [64].
Anionic model membranes promote hIAPP amyloid
formation in vitro and more highly charged systems have a
larger effect for experiments conducted at high peptide to
lipid ratios [107]. The mechanism of membrane catalyzed
hIAPP aggregation is not completely understood, but helical
intermediates are thought to be important [90, 91, 107–
109]. Much of the work on hIAPP-membrane interactions
has used model membranes comprised of pure anionic
lipids, such as phosphatidylglycerol or phosphatidylserine,
or mixtures of anionic lipids with zwitterionic lipids, such
as phosphocholine. The content of anionic lipid typically
ranges from 50 or more to 20 mole % in these systems,
which is much higher than that found in 𝛽-cells [110].
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The phospholipid composition of the 𝛽-cell is also very
different frommost model systems. In addition, 𝛽-cell mem-
branes contain cholesterol and the 𝛽-cell plasma membrane
is asymmetric with the anionic lipids localized on the inner
leaflet. These considerations naturally lead to the question
of how well model membranes recapitulate the situation in
vivo. Model membranes made up of the phospholipids found
in 𝛽-cell membranes, but lacking cholesterol, also accelerate
hIAPP amyloid formation, as do anionic model membranes
that are capable of forming lipid rafts [110–112]. The effects of
cholesterol have also been examined [113].
12. Does Islet Amyloid Have an Extracellular
or Intracellular Origin?
The initiation site for islet amyloid formation in vivo is con-
troversial and there are conflicting reports in the literature.
Amyloid deposits detected in T2D appear to be extracellular
and initial studies with transgenic mice were consistent with
extracellular deposition. However other studies with rodent
models in which IAPP is overexpressed are consistent with an
intracellular origin [4, 114]. It is worth bearing in mind that
some transgenic mouse models have high copy numbers of
the human IAPP gene and can produce high levels of hIAPP.
Significant overproduction of the polypeptide could play a
role. In contrast to the mouse studies, a recent investigation
used a cultured transgenic islet model to show that secretion
of IAPP is an important factor in 𝛽-cell toxicity and islet
amyloid formation. Two complimentary sets of reagents were
employed: one that inhibited IAPP secretion, but main-
tained the level of production of IAPP and a second that
increased IAPP secretion but did not increase the amount of
IAPP produced. Inhibiting IAPP secretion reduced amyloid
formation, but increasing secretion increased toxicity and
amyloid formation [115]. The results are consistent with an
extracellular origin of islet amyloid. The differences between
the various studies might be related to the level of production
of hIAPP [4, 114–116]. Clarifying whether islet amyloid has
an intracellular or extracellular origin is important since the
answer might impact therapeutic strategies and drug design.
13. IAPP Toxicity Impacts Type-2 Diabetes
and Islet Cell Transplantation
Interest in islet amyloid has undergone resurgence due to the
realization that𝛽-cell dysfunction anddeath and the loss of𝛽-
cell mass are key features of T2D [117, 118]. 𝛽-cell dysfunction
and the decline in𝛽-cell mass are attributed to several factors,
including glucolipotoxicity, inflammation, accumulation of
cholesterol, and islet amyloid formation [117–122].
Islet amyloid deposition is also a key factor contributing
to the failure of islet cell transplants. Islet amyloid has
been detected in transplanted human islets in a patient
that suffered islet graft failure and has been shown to form
rapidly after transplantation of human islets into nude mice
[4, 123–125]. Islet amyloid formation in the mouse studies
is correlated with the loss of 𝛽-cells and occurs before
the recurrence of hyperglycemia. Porcine IAPP is far less
amyloidogenic than hIAPP and the prevention of amyloid
formation by transplantation of porcine islets prolongs islet
graft survival [126]. Recent work also highlights a role for
hIAPP aggregation and hyperamylinemia in cardiovascular
complications of diabetes [16, 127].
14. Multiple Mechanisms of hIAPP Induced
𝛽-Cell Toxicity Have Been Proposed
A range of mechanisms have been proposed to account for
the toxic effects of amyloidosis, but the exact causes of cell
death are still not completely defined. In some cases, amyloid
fibril deposits disrupt tissue and can lead to organ failure, but,
in most cases, activation of overlapping cellular mechanisms
and downstream signaling pathways are believed to lead to
toxicity. These include receptor-mediated mechanisms and
non-receptor-mediated processes.
ER stress, defects in autophagy, the enhanced production
of proinflammatory cytokines, mitochondrial membrane
damage, permeabilization of cell membranes, activation of
Calpain-2, receptor-mediated mechanisms linked to oxida-
tive stress, and the activation of cell death signaling pathways
have all been proposed to contribute to IAPP toxicity [128–
147]. Here we provide an overview; more information can be
found in other recent review articles [4, 15, 116, 130].
Defects in autophagy play a role in the toxicity of other
amyloidogenic proteins. Upregulation of autophagy is a
common protective response to the accumulation of toxic
amyloidogenic aggregates in degenerative disease. However,
autophagocytosis and lysosomal degradation of amyloido-
genic polypeptides are not always entirely successful and
the resulting accumulation of amyloidogenic aggregates can
lead to autophagy-mediated lysosomal dysfunction and cell
death. Overexpression of hIAPP in 𝛽-cells has been reported
to lead to impaired autophagy [135, 143, 146]. Inhibition
of autophagy-lysosomal degradation has been shown to
enhance hIAPP induced 𝛽-cell apoptosis, while stimulation
of autophagy protected against IAPP toxicity [135, 146].
Defects in ER stress, endoplasmic reticulum associated
protein degradation (ERAD), and the unfolded protein
response (UPR) have all been reported to induce 𝛽-cell
death by hIAPP aggregates. ProIAPP and partially processed
proIAPP may be one of deleterious species in cases where
toxicity arises from intracellular aggregates since proIAPP
miss-processing has been shown to occur in diabetes and
posttranslational modification is completed in the Golgi and
insulin secretory granules [4, 7, 8]. The role of ER stress in
hIAPP mediated toxicity in vivo is controversial. Transgenic
mouse studies using mice that overexpress hIAPP led to the
proposal that ER stress is a key contributor to hIAPP induced
𝛽-cell dysfunction and exogenously added hIAPP has been
reported to induce ER stress [114, 141]. On the other hand,
ER stress was not detected in studies of cultured islets that
produce IAPP at more physiological levels [142].
Chronic inflammationmay be an important contributing
factor to amyloidosis toxicity and it is frequently observed
in local and systemic amyloidosis. hIAPP aggregates can
contribute to 𝛽-cell dysfunction by triggering a localized
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inflammatory response by stimulating inflammasome activ-
ity [136, 137]. Inflammasomes are multiprotein assemblies
that recognize a diverse range of proinflammatory stimuli
and produce active caspase-1. Caspase-1 in turn activates the
cytokines IL-1𝛽 and IL-18 by cleaving their proforms. IL-1𝛽 is
thought to play a direct role in hIAPP induced 𝛽-cell death
and dysfunction [136, 137].
Amyloid formation by hIAPP induces apoptosis in cell
culture and in isolated human islets, but the pathways that
lead to IAPP induced 𝛽-cell apoptosis are not yet fully eluci-
dated [128–134]. The JNK pathway mediates 𝛽-cell apoptosis
in islets and in cultured cells exposed to high concentrations
of hIAPP and is upregulated in response to amyloid formation
by endogenous hIAPP [133]. Interaction of exogenous or
endogenous hIAPP aggregates with Fas, also known as the
death receptor, leads to caspase-3 activation, while deletion
of Fas protects 𝛽-cells from hIAPP induced toxicity and
inhibition of caspase-3 in vivo protects 𝛽-cells from hIAPP
induced 𝛽-cell apoptosis [15, 134].
IAPP toxicity has also been proposed to result from
the perturbation of membrane integrity [144, 145, 148].
The efficiency with which hIAPP permeabilizes membranes
depends on a range of factors including the lipid to peptide
ratio, the lipid composition, pH, and ionic strength. IAPP
interacts significantly more strongly with model membranes
that contain a high fraction of anionic lipids. Commonly
used model systems contain a much higher percentage of
anionic lipids than that found in the 𝛽-cell membrane [110]
and usually lack cholesterol and gangliosides. These are
important considerations since high percentages of anionic
lipids significantly promote IAPP membrane interactions
and because gangliosides and cholesterol modulate hIAPP
membrane interactions [111, 148]. In addition, there is experi-
mental evidence that membrane gangliosides and cholesterol
play a role in the uptake and clearance of hIAPP [111, 148].
More physiologically relevant model membrane systems are
starting to be employed in biophysical investigations and
should provide new insights [110–112].
The correlation between in vitro biophysical studies using
modelmembranes and in vivo toxicity is not clear and caution
needs to be employed when extrapolating from biophysical
studies that utilize simple model membranes to the in vivo
environment. For example, variants of hIAPP that do not
induce 𝛽-cell death in vivo and are not toxic in vitro can
disrupt standard model membranes in vitro and can do
so as effectively as hIAPP [149]. It is also worth noting
that exogenously added IAPP has been reported to induce
different toxic effects on closely related cell types, arguing
that nonspecific membrane disruption cannot be the only
mechanism of toxicity [150].
Mechanistic studies of IAPP induced model membrane
disruption are an active area of research and a variety ofmod-
els have been proposed. Some studies provide evidence for a
detergent or carpeting mechanism while others have argued
for a pore-like mechanism.The process of fiber growth at the
membrane surface can contribute tomembrane disruption in
some cases, while other studies have shown that formation of
𝛽-structure is not required to disrupt membranes [149, 151–
156]. It is possible thatmultiplemechanisms are operative and
the specific mechanism depends on the membrane system
under investigation [157, 158].Muchmore information on the
mechanisms of membrane disruption can be found in other
contributions to this issue.
15. Macromolecular Crowding Impacts the
Rate of Amyloid Formation and Does So by
Multiple Mechanisms
The cell is an inherently crowded environment, containing
numerous proteins and other macromolecules as well as
osmolytes, and there is no guarantee that a proteinwill behave
the same in dilute solution and in a crowded environment.
The effects of molecular crowding and osmolytes on the
stability and folding of globular proteins are well studied and
are still an active area of research. Early work focused on
inert crowders and the role of excluded volume effects, but
more recent efforts have been directed at better mimics of
the cellular environment and consideration of interactions
beyond excluded volume [159–163]. Indeed, it is now clear
that the effects of many crowding agents, and by implication
the cellular environment, cannot be explained solely on the
basis of excluded volume. Less work has been reported on
the effects of crowding and osmolytes on amyloid formation,
but this is an active area and recent papers have appeared
that have examined the effects of osmolytes and crowders
on amyloid formation by hIAPP and other proteins [164–
169]. Two themes which have emerged from recent studies
are that the impact of crowding on amyloid formation goes
beyond excluded volume effects and specific interactions
of the amyloidogenic protein of interest with biologically
relevant crowding agents can make significant contributions.
The effects of crowding agents and osmolytes on amyloid
formation by IAPP are reviewed in detail in this volume by
Gao and Winter [169].
16. Nontoxic Bioactive Variants of IAPP
with Improved Solubility Are Clinically
Relevant for the Treatment of Type-1
Diabetes and Obesity
Coadministration of IAPP with insulin helps to normalize
fluctuating glucose levels to a greater degree than is possible
with insulin alone; however the extreme tendency of IAPP
to aggregate and its amyloidogencity and toxicity prevent
its direct use as an adjunct to insulin therapy [170–174].
A nonamyloidogenic analog of human IAPP, denoted by
Pramlintide, in which residues 25, 28, and 29 were replaced
by proline is approved by the FDA for use in type-1 and
type-2 diabetes [170, 171]. Pramlintide was designed based
on comparison of the sequences of rat and human IAPP
and is simply human IAPP with the three Pro substitutions
found in the rat polypeptide. Ideally, Pramlintide would be
formulated with insulin and coadministrated. Unfortunately,
Pramlintide is not soluble at the appropriate pH.There is also
interest in combining leptin and hIAPP for the treatment of
obesity [175]. However, coformulation is also difficult in this
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Figure 4: Primary sequences of human IAPP, Pramlintide, and four rationally designed sequences with improved solubility, denoted by Seq-
A through Seq-D. The final sequence, denoted by hIAPP∗, represents a family of designed bioactive analogs of human IAPP in which one of
the Asn residues indicated with a (∗) has been glycosylated.
case because of the poor solubility of hIAPP and Pramlintide.
Recent efforts at developing more soluble analogs of hIAPP
have utilized a number of approaches. Nontoxic variants of
hIAPP with considerably improved solubility at pH 7.4 have
been developed by rationally redesigning the sequence to
incorporate strategic proline residues together with addi-
tional charges (Figure 4) [176]. An alternative approach has
employed the strategy of conjugating groups to hIAPP.
Engineering the polypeptide by the selective modification
of specific Asn residues with carbohydrates or by attaching
polyethylene glycol to the side chain and N-terminal amino
group of Lys-1 has led to bioactive analogs with improved
properties [177, 178]. An interesting feature of the Asn
modification work is that the effects of the modifications on
the normal activity of hIAPP were found to depend on the
site modified and thus provide indirect information about
regions of hIAPPwhich are critical for receptor binding [177].
A fourth approach hasmade use of N-methylation and builds
upon the development of N-methylated hIAPP analogs as
potent inhibitors of wild type aggregation and toxicity [34].
N-methylated analogs have been reportedwhich are bioactive
and nonamyloidogenic and which inhibit amyloid formation
by insulin [179, 180]. Collectively, these different approaches
demonstrate that there is considerable potential for the design
of hIAPP therapeutics with improved properties.
17. Conclusions
Impressive progress has been made in studies of amyloid
formation by hIAPP, but important challenges remain. These
include identifying the initiation site(s) of amyloid formation
in vivo; defining the nature of the toxic species; elucidating the
mechanisms of islet amyloid formation in vivo and in vitro;
understanding the mechanisms of 𝛽-cell death; defining the
mechanisms of hIAPP clearance in vivo and the role such
processes may play in IAPP toxicity. Experimental challenges
include relating reductionist biophysical experiments to the
situation in vivo and understanding the connection between
mouse models that highly overexpress hIAPP and human 𝛽-
cell physiology. Although not discussed in this review, the
development of inhibitors of hIAPP toxicity is also an area
that warrants further effort. There are no clinically approved
inhibitors of IAPP toxicity and very few, if any, effective
“drug-like” inhibitors of IAPP amyloid formation have been
reported in the literature.
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